Lipocine (LPCN) vs Shuttle Pharmaceuticals (SHPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Lipocine (LPCN) has outperformed Shuttle Pharmaceuticals (SHPH) over the past year, losing 53.2% versus a loss of 78.2%. Shuttle Pharmaceuticals is the larger company by market cap ($16.6 million vs $16.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LPCN | SHPH |
|---|---|---|
| Share price | $1.48 | $3.49 |
| Market cap | $16.39M | $16.63M |
| 1-day change | -1.33% | -10.51% |
| YTD return | -81.57% | -80.61% |
| 1-year return | -53.16% | -78.19% |
| 5-year return | -92.30% | — |
| EPS (TTM) | $-1.32 | $-16.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.98M | — |
| Revenue growth (YoY) | -82.35% | — |
| Net income (latest FY) | $-9.63M | $-11.72M |
| Operating margin | -524.69% | — |
| Net margin | -487.06% | — |
| 52-week high | $12.37 | $44.40 |
| 52-week low | $1.36 | $2.58 |
| Distance from 52-week high | -88.04% | -92.14% |
| Analyst consensus | none | — |
| Avg. price target upside | +237.84% | — |
| Average volume | 1.84M | 41.80K |
| Shares outstanding | 11.07M | 4.76M |
| Employees | 14 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LPCN has outperformed SHPH by 25.0 percentage points over the past year.
About Lipocine
LPCN stock →Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
About Shuttle Pharmaceuticals
SHPH stock →Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
LPCN vs SHPH FAQ
Which is bigger, Lipocine or Shuttle Pharmaceuticals?
Shuttle Pharmaceuticals (SHPH) is larger, with a market capitalization of $16.63M compared with $16.39M for Lipocine (LPCN).
Which stock has performed better over the past year, LPCN or SHPH?
LPCN returned -53.16% over the past 12 months, compared with -78.19% for SHPH (price return, excluding dividends). Past performance does not predict future results.
Are Lipocine and Shuttle Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.